Glomerulonephritis is an immune-mediated inflammatory disease affecting the renal glomeruli and can present as acute or chronic nephritic syndromes. It includes diverse etiologies and pathologies and can progress to chronic kidney disease or end-stage renal disease if not treated. Clinical manifestations often include hematuria, proteinuria, edema, and hypertension.
Crohn’s disease is linked to kidney stones, dehydration and rare serious kidney complications. Monitoring, hydration and attention to medication-related risks can help protect kidney health.
Bayer's Phase III FIND-CKD trial shows finerenone significantly slows kidney function decline in non-diabetic chronic kidney disease patients. The drug met its primary endpoint with improved eGFR slope over 32 months, marking its fifth consecutive positive Phase III trial. Bayer plans to submit the data to the FDA for label expansion into non-diabetic CKD.
The FDA has approved Filkri (filgrastim-laha), a biosimilar to Neupogen, for cancer patients at risk of infection due to chemotherapy and other indications. The approval marks Accord BioPharma's sixth biosimilar product.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07431931 |
Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria |
NOT_YET_RECRUITING | NA |
| NCT07096986 |
Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy |
NOT_YET_RECRUITING | PHASE2 |
| NCT06889948 |
The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland |
RECRUITING | PHASE2 |
| NCT06858319 |
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. |
RECRUITING | PHASE3 |
| NCT06835322 |
Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis |
RECRUITING | PHASE2 |
| NCT06792448 |
Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics Study |
NOT_YET_RECRUITING | |
| NCT06753942 |
ANTI-SARS-CoV-2 SEROCONVERSIO IN IMMUNE-MEDIATED KIDNEY DISEASES |
COMPLETED | |
| NCT05761938 |
A Study of Rituximab in Frontline Therapy for Glomerulonephritis |
RECRUITING | |
| NCT05517980 |
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis |
NOT_YET_RECRUITING | PHASE2 |
| NCT05505955 |
Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency |
COMPLETED | PHASE1 |
